Key result
Real-world study compares NOACs to vitamin K antagonists in AF patients with cancer.
Why the study?
Evidence on the safety and effectiveness of NOACs in AF patients with cancer was rather limited.
Key points are not available for this paper at this time.
Population
Real-world patients with AF and cancer
Comparison
NOACs vs VKAs
Design
Meta-analysis of retrospective observational studies
Real-world data may support NOAC use in AF with cancer; extends RCT evidence but leaves need for dedicated trials open.
Background: Evidence on the safety and effectiveness of Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) in Atrial Fibrillation (AF) patients with cancer is rather limited, so we performed this meta-analysis to compare the efficacy and safety of NOACs with vitamin K antagonists (VKAs) in real-world patients with AF and cancer.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2021) studied this question. Non-vitamin K antagonist oral anticoagulants (NOACs) were evaluated against vitamin K antagonists for efficacy and safety in real-world patients with atrial fibrillation and cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: